Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis
- PMID: 16106061
- DOI: 10.1385/IR:32:1-3:085
Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis
Abstract
Abnormal immunoglobulin synthesis within the central nervous system is a common finding in patients with multiple sclerosis (MS) that is often used for diagnosis. However, it is not clear whether antibodies, or the B-cells and plasma cells that make them, are critical to the pathogenesis of MS. Here we review the descriptive data that suggest a role for antibody in the pathogenesis of MS. The results of B-cell and antibody depletion studies in the animal model for MS, experimental autoimmune encephalomyelitis, are summarized, as well as early data using a chimeric monoclonal antibody to deplete B-cells in patients with MS.
Similar articles
-
C3d binding to the myelin oligodendrocyte glycoprotein results in an exacerbated experimental autoimmune encephalomyelitis.J Immunol. 2007 Mar 1;178(5):3323-31. doi: 10.4049/jimmunol.178.5.3323. J Immunol. 2007. PMID: 17312184
-
Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions.Mult Scler. 2006 Aug;12(4):369-74. doi: 10.1191/1352458506ms1290oa. Mult Scler. 2006. PMID: 16900750
-
T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis.Glia. 2001 Nov;36(2):220-34. doi: 10.1002/glia.1111. Glia. 2001. PMID: 11596130 Review.
-
IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein.Int Immunol. 1998 May;10(5):703-8. doi: 10.1093/intimm/10.5.703. Int Immunol. 1998. PMID: 9645618
-
The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis.J Neural Transm Suppl. 2000;(58):123-33. doi: 10.1007/978-3-7091-6284-2_10. J Neural Transm Suppl. 2000. PMID: 11128602 Review.
Cited by
-
The potential role of B cell-targeted therapies in multiple sclerosis.Drugs. 2010 Dec 24;70(18):2343-56. doi: 10.2165/11585230-000000000-00000. Drugs. 2010. PMID: 21142258 Review.
-
Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice.J Autoimmun. 2011 Sep;37(2):122-8. doi: 10.1016/j.jaut.2011.05.001. Epub 2011 May 31. J Autoimmun. 2011. PMID: 21632210 Free PMC article. Review.
-
Development of anti-CD20 therapy for multiple sclerosis.Exp Cell Res. 2011 May 15;317(9):1312-8. doi: 10.1016/j.yexcr.2011.04.002. Epub 2011 Apr 12. Exp Cell Res. 2011. PMID: 21510932 Free PMC article. Review.
-
B cells as a target of immune modulation.Ann Indian Acad Neurol. 2009 Oct;12(4):221-5. doi: 10.4103/0972-2327.58275. Ann Indian Acad Neurol. 2009. PMID: 20182568 Free PMC article.
-
Peripheral nerve protein expression and carbonyl content in N,N-diethlydithiocarbamate myelinopathy.Chem Res Toxicol. 2007 Mar;20(3):370-9. doi: 10.1021/tx6003453. Epub 2007 Feb 27. Chem Res Toxicol. 2007. PMID: 17323979 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical